Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424213 · ClinicalTrials.gov registry record
Race-related Alternative Splicing: Novel Targets in Prostate Cancer
A clinical trial, sponsored by Duke University.
- Completed
- Registry status
- 169
- Enrollment target
NCT03424213 is a clinical trial that has completed, run by Duke University. The registered enrollment target is 169 participants.
The verdict
NCT03424213 has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- 169 participants
- Enrollment target
Study Summary
Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnaire data, and ancestral genotyping data will be obtained from the racially diverse and federally funded North Carolina-Louisiana PCa Project (NC-LA PCaP). We will use 33 tissue specimens from each of the following 6 groups (n=198 total): white low aggressive, white intermediate aggressive, white high aggressive, AA low aggressive, AA intermediate aggressive and AA high aggressive. The aforementioned tissues will first be screened for tumor content and Gleason grade by a genitourinary pathologist. To identify race-related splice variants, RNA will be isolated for targeted sequencing of prioritized race-related alternatively spliced genes using the NimbleGen SeqCap Target Enrichment, SeqCap RNA System to capture regions of interest and the Illumina HiSeq sequencing platform to sequence these regions at a depth and coverage sufficient to accurately call alternative splicing events.
Interventions
- OTHER No interventions - retrospective data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2021-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03424213
The ClinicalTrials.gov registry entry for NCT03424213 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 169 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No interventions - retrospective data collection is the first listed.
NCT03424213 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03424213 about?
NCT03424213 is a clinical study titled "Race-related Alternative Splicing: Novel Targets in Prostate Cancer". Data from evaluating prostate cancer (PCa) biopsy tissue from AA and white patients has led to the discovery of alternative splicing as a novel molecular mechanism underlying more aggressive PCa in AA men. Coded archival radical prostatectomy tissue specimens and annotated clinical data, questionnai...
What is the current status of trial NCT03424213?
This trial is currently completed. The enrollment target is 169 participants. The study started on 2018-01-30. Estimated completion is 2021-07-14.
What interventions are being tested in trial NCT03424213?
The interventions under investigation include: No interventions - retrospective data collection (OTHER).
Who is sponsoring clinical trial NCT03424213?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.